CureApp, founded in 2014 by two physicians with programming skills, is a leading digital health company in the vertical of “medical apps exhibiting therapeutic effects against diseases” in the clinical field. It has raised more than $20 million in funding and developed a pipeline of digital therapeutic products for diseases including nicotine addiction, NASH (non-alcoholic steatohepatitis) and hypertension. CureApp for nicotine addiction, jointly developed with Keio University’s Schools of Medicine, currently is under a clinical trial for regulatory approval and reimbursement of national health insurance, which would be a first for a therapeutic software in Japan.

Visit the CureApp website

Abonnez-vous aux mises à jour

Une mise à jour hebdomadaire de ce qui est à l'Agenda mondial

© 2021 World Economic Forum

Politique de confidentialité et conditions d’utilisation du service